⌕
Relay Therapeutics · RLAY · Nasdaq
Tenet 43 · Weak
Compare
$17.27−4.53%At closeTenet 43 · Weak
$17.27−0.82 (−4.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Relay Therapeutics (RLAY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 11, 2026 · 14:39 ET
Relay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Relay Therapeutics, Inc. ( RLAY ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Developm…

● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at t…

● GlobeNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living …

● GlobeNewsWireOct 28, 2026 · 16:12 ETCOMPANY'S OWN WORDS
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living …

● Defense WorldOct 12, 2026 · 01:59 ET
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)

Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on…

● Defense WorldOct 11, 2026 · 05:39 ET
Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in Stock

Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $18.10, f…

● Seeking AlphaSep 16, 2026 · 13:41 ET
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Defense WorldSep 16, 2026 · 04:08 ET
Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY

Squarepoint Ops LLC lessened its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 48.3% during a recent quarter, according to the company in its most recent disclosure with the SEC. The institutional inve…

● Defense WorldSep 15, 2026 · 04:02 ET
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAY

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The institut…

● Seeking AlphaSep 10, 2026 · 07:47 ET
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript…

● Defense WorldSep 10, 2026 · 03:13 ET
Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY

Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquire…

● Defense WorldSep 7, 2026 · 04:20 ET
Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY

Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during a recent quarter, according to the company in its most recent filing with the Securities and Excha…

● The Motley FoolSep 2, 2026 · 13:00 ET
Relay Therapeutics CFO Sells 17,717 Shares for $350,000

The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.…

● GlobeNewsWireSep 1, 2026 · 16:46 ETCOMPANY'S OWN WORDS
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living…

● Defense WorldAug 20, 2026 · 03:24 ET
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE

Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The in…

● Zacks Investment ResearchAug 17, 2026 · 11:01 ET
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just RLAY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.